Nachrichten

PEKING, Mai 18, 2021 - Lepu Medical Technology (Beijing) Co., Ltd. („ Lepu Medical “), ein weltweit führendes Unternehmen, das sich auf die Entwicklung, Herstellung und Vermarktung von medizinischen High-Tech-Geräten und-Geräten spezial isiert hat, Am 14. Mai veranstaltete ein virtuelles „ Seminar über COVID-19 Methoden zur Erkennung “, um Dieorie und Best Practices auszu tauschen und die globale COVID-19 kontrolle und-prävention in China und auf der ganzen Welt weiter zu fördern.

Die seminar, which included a virtual training session and a virtual visit to Lepu Medical’s headquarters in Beijing, was part of the seven-day “Seminar on COVID-19 Methods For Detection,” sponsored by China’s Ministry of Commerce and organized by Beijing Holley-Cotect Pharmaceuticals Co., Ltd. Die seminar aimed to help other countries and regions to control the pandemic by sharing China’s advanced prevention and control experience. 

Das Seminar wurde virtuell über Live-Streaming-Videos abgehalten und umfasste Fragen-und Antwort sitzungen, gemeinsame Seminare, Cloud-Besuche und andere virtuelle Formate. Insgesamt 77 Teilnehmer, darunter medizinische Mitarbeiter, Regierungs mitarbeiter und Forscher in wissenschaft lichen Forschungs einrichtungen aus neun Ländern, darunter Kenia, Mauritius, Venezuela, Peru, Ukraine, Sri Lanka, Irak, Äthiopien und Iran, nahmen an dem von veranstalteten Vortrag und Cloud-Besuch teil Lepu Medical.

During the seminar, Lepu Medical invited Dr. Jing Yu from the Wuhan Hospital of Traditional Chinese and Western Medicine to deliver a training lecture on basic knowledge and practical experiences of SARS-COV-2 detection, antigen rapid tests, and biochemical indicators for diagnosis. Die training course covered the closed loop and seamless SARS-COV-2 detection process from sampling, sample transfer, sample receipt, testing, result reporting and medical waste treatment in various settings including medical institutions, communities, mass screening sites and public places. Die seminar, which was well-received by attendees, included a question and answer session in which Dr. Jing Yu and representatives from Lepu Medical answered detailed questions on COVID-19 detection methods, and provided best practice advice to attendees. 

Lepu Medical’s 2019-nCoV Antigen Schnelltest Kit (kolloidale Gold immuno chromato graphie), a simple screening method for COVID-19 that delivers quick results with high negative predictive value (NPV), was held up as an example by Dr. Yu during the training session. Die antigen test method, which is non-invasive, simple to use, cost-efficient, convenient, rapid, stable and accurate has shown high sensitivity of 95.06% and high specificity of 99.62% in clinical trials in IPE Center for Clinical Laboratory, a Lepu Medical subsidiary. Results can be quickly retrieved in 15 minutes. Lepu Medical provides both Lepu Professional Antigen test kits for use by medical institutions and Lepu Antigen self-test kits for individual self-test use, to support diverse testing needs. Die Lepu Antigen self-test kit is already approved by BfArM and available in Germany. 

“(For the antigen rapid test,) the positive results can be seen in the early stage after the symptoms (emerged) or in the infection,” said Dr. Yu, addressing participant questions raised about test timing and sensitivity during the lively Q&A session following her lecture, “Die sensitivity of the antigen detection depends on the prevalence of the virus. Die positive rate of the antigen rapid test is useful in the high prevalent area. If the viral load of the sample is high, the sensitivity of the antigen test and PCR test can be the same.  All biomarkers combined together can be the most effective.”

In addition to the 2019-nCoV Antigen Schnelltest Kit (kolloidale Gold immuno chromato graphie), Lepu Medical offers other comprehensive diagnostic solutions including nucleic acid series products and solutions, which provide standard tests for COVID-19 diagnosis, and neutralization antibody test products to detect the effectiveness of COVID-19 vaccines in the post-pandemic period. Other COVID-19 products and solutions include sample collection kits, manual sample extraction kits, automated sample extractors, nucleic acid test kits, real-time PCR systems for standard clinical nucleic acid diagnostics, and antibody test kits and systems for vaccine effect evaluation.

Lepu Medical has been providing proactive support to control the COVID-19 pandemic from an early stage. In early 2020, during the outbreak in China, Lepu Medical started emergency production of medical equipment supplies and donated more than RMB5 million of personal protective equipment (PPE), medical devices and cash to severely impacted areas. Die company also developed an online free medical consulting system “Doctor Lepu” to assist patients remotely while supporting social distancing. Lepu Medical subsidiaries also dispatched volunteers and a medical aid team to the city of Wuhan and provided mass COVID-19 nucleic acid testing in Beijing where the company is headquartered. Lepu Medical’s products were also widely used across China’s hospitals, medical centers and COVID-19 testing sites. Diese products included Lepu Medical’s automatic PCR analysis system, personal forehead thermometers, pulse oximeters, monitors, electrocardiographs, household oxygen generators and pharmaceutical products.

Als globales Unternehmen in mehr als 80 Ländern und Regionen mit über 20 globalen OEM-Partnern hat Lepu Medical sein globales Netzwerk und seine Ressourcen in den Bereichen Forschung und Entwicklung, Herstellung und Vertrieb eingesetzt, um die weltweiten Bemühungen zur Bekämpfung von COVID-19 zu unterstützen. Verschiedene relevante Produkte des Unternehmens wurden in Europa mit einem CE-Zertifikat aus gezeichnet, von der US-amerikanischen Food and Drug Administration (FDA) zugelassen und zur Bekämpfung der Pandemie an über 140 Länder verteilt. Lepu Medical hat regelmäßige Massen tests in mehreren Ländern unterstützt und bei der organisierten Wiedereröffnung von Schulen in Österreich mit über 20 Millionen Antigen-Testkits unterstützt, um ab Januar 2021 landesweite Tests durch zuführen. Das Lepu SARS-CoV-2 Antigen-Schnelltest kit, das auf der chinesischen Whitelist für den Export aufgeführt ist, ist vom offiziellen Institut PEI in Deutschland zertifiziert und vom Bundes institut für Arzneimittel und Medizin produkte (BfArM) für Selbst tests speziell zugelassen.

Upholding the company’s spirit of integrity, quality and scientific innovation, Lepu Medical will continue to focus on combating the COVID-19 pandemic and go above and beyond to provide the best quality of products and services to satisfy the needs of healthcare professionals and patients.